Contact allergy in atopic individuals in relation to allergen-specific immunotherapy
(2016) In European Journal of Dermatology 26(3). p.271-280- Abstract
Background: Type I sensitizations and atopic dermatitis (AD) often appear in the same patient. Beneficial effects of allergen-specific immunotherapy (ASIT) in patients with bothADand type I allergies have been reported. The predisposing role of AD to the development of type IV sensitization is discussed. Whether ASIT for type I allergy also influences type IV allergies is unknown. Objectives: To compare the number of contact allergies between patients with and without AD, before and after one year’s treatment with ASIT. Materials and Methods: A controlled, single-blind multicentre study of children/adults with allergic asthma and/or rhinoconjunctivitis, treated or untreated with ASIT, was performed. The history of AD was collected using... (More)
Background: Type I sensitizations and atopic dermatitis (AD) often appear in the same patient. Beneficial effects of allergen-specific immunotherapy (ASIT) in patients with bothADand type I allergies have been reported. The predisposing role of AD to the development of type IV sensitization is discussed. Whether ASIT for type I allergy also influences type IV allergies is unknown. Objectives: To compare the number of contact allergies between patients with and without AD, before and after one year’s treatment with ASIT. Materials and Methods: A controlled, single-blind multicentre study of children/adults with allergic asthma and/or rhinoconjunctivitis, treated or untreated with ASIT, was performed. The history of AD was collected using questionnaires. The number of contact allergies was assessed by patch testing with a baseline series. Results: 205 individuals completed the study; 133 treated with ASIT (exposed) and 72 before starting ASIT (unexposed). For participants with AD, significantly more contact allergies were found in the groups of all children (p = 0.002), all exposed children (p<0.001), and all exposed study persons (p = 0.013). Independent of AD, significantly more contact allergies were noted in the groups of all unexposed adults (p = 0.004) and all unexposed study persons (p = 0.004). Conclusions: The higher number of contact allergies in patients with AD indicates that AD may be a risk factor for type IV sensitization in those with allergic asthma and/or rhinoconjunctivitis. The lower number of contact allergies in patients exposed to ASIT suggests an immunomodulatory effect on type IV sensitization.
(Less)
- author
- Siemund, Ingrid LU ; Hindsén, Monica LU ; Netterlid, Eva LU ; Güner, Nuray and Bruze, Magnus LU
- organization
- publishing date
- 2016-05-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Allergen-specific immunotherapy, Allergic contact dermatitis, Atopic eczema, Cutaneous delayed-type hypersensitivity, Patch testing, Type I sensitization
- in
- European Journal of Dermatology
- volume
- 26
- issue
- 3
- pages
- 10 pages
- publisher
- John Libbey Eurotext
- external identifiers
-
- scopus:85006094923
- pmid:27193374
- wos:000378782900008
- ISSN
- 1167-1122
- DOI
- 10.1684/ejd.2016.2765
- language
- English
- LU publication?
- yes
- id
- b0650ed7-9304-4b2b-b680-16c8894d59bc
- date added to LUP
- 2016-12-30 10:12:05
- date last changed
- 2024-07-12 23:51:51
@article{b0650ed7-9304-4b2b-b680-16c8894d59bc, abstract = {{<p>Background: Type I sensitizations and atopic dermatitis (AD) often appear in the same patient. Beneficial effects of allergen-specific immunotherapy (ASIT) in patients with bothADand type I allergies have been reported. The predisposing role of AD to the development of type IV sensitization is discussed. Whether ASIT for type I allergy also influences type IV allergies is unknown. Objectives: To compare the number of contact allergies between patients with and without AD, before and after one year’s treatment with ASIT. Materials and Methods: A controlled, single-blind multicentre study of children/adults with allergic asthma and/or rhinoconjunctivitis, treated or untreated with ASIT, was performed. The history of AD was collected using questionnaires. The number of contact allergies was assessed by patch testing with a baseline series. Results: 205 individuals completed the study; 133 treated with ASIT (exposed) and 72 before starting ASIT (unexposed). For participants with AD, significantly more contact allergies were found in the groups of all children (p = 0.002), all exposed children (p<0.001), and all exposed study persons (p = 0.013). Independent of AD, significantly more contact allergies were noted in the groups of all unexposed adults (p = 0.004) and all unexposed study persons (p = 0.004). Conclusions: The higher number of contact allergies in patients with AD indicates that AD may be a risk factor for type IV sensitization in those with allergic asthma and/or rhinoconjunctivitis. The lower number of contact allergies in patients exposed to ASIT suggests an immunomodulatory effect on type IV sensitization.</p>}}, author = {{Siemund, Ingrid and Hindsén, Monica and Netterlid, Eva and Güner, Nuray and Bruze, Magnus}}, issn = {{1167-1122}}, keywords = {{Allergen-specific immunotherapy; Allergic contact dermatitis; Atopic eczema; Cutaneous delayed-type hypersensitivity; Patch testing; Type I sensitization}}, language = {{eng}}, month = {{05}}, number = {{3}}, pages = {{271--280}}, publisher = {{John Libbey Eurotext}}, series = {{European Journal of Dermatology}}, title = {{Contact allergy in atopic individuals in relation to allergen-specific immunotherapy}}, url = {{http://dx.doi.org/10.1684/ejd.2016.2765}}, doi = {{10.1684/ejd.2016.2765}}, volume = {{26}}, year = {{2016}}, }